Kornimate/medical-research-clean huggingface dataset:
efficacy of lianhua qingwen in treating patients infected with the omicron variant of the covid-19

Conditions: COVID-19 Pneumonia

Summary: a retrospective analysis was conducted on patients infected with the omicron variant of covid-19 diagnosed from august 2022 to now. patients were divided into observation groups and control groups according to whether or not oral lianhua qingwen granules were used. through data analysis and follow-up, the effectiveness of lianhua qingwen in treating patients infected with the omicron variant of covid-19 was discussed.


Eligibility criteria:
inclusion criteria: * for patients infected with the omicron variant, the diagnostic criteria are confirmed cases of covid-19 and clinical classification according to the diagnostic criteria of prevention and control protocol for covid-19 (trial eighth edition) issued by the national health and construction commission. * the clinical symptoms were classified as mild or ordinary. * they have been vaccinated against the covid-19. exclusion criteria: * patients receiving antiviral or antibiotic drugs * severe and critical patients with covid-19. * patients with chronic respiratory diseases, bacterial infections of the respiratory system, and other respiratory diseases affecting the study. * patients with serious primary diseases of the heart, brain, lung, liver, kidney, and hematopoietic systems, as well as mental diseases. * allergic reaction to lianhua qingwen granules. * excluded patients treated with the same drug as lianhua qingwen.
effect of liraglutide on blood glucose control in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in japan. the trial aims for comparison of the effect on glycaemic control of liraglutide, compared to sulfonylurea (su treatment), as assessed by hba1c after 24 and 52 weeks in subjects with type 2 diabetes. trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * diet/exercise therapy with or without an oral anti-diabetic drug for at least eight weeks * hba1c greater than or equal to 7.0% and less than 10.0% * bmi (body mass index) less than 35 kg/m2 exclusion criteria: * treatment with insulin within the last 12 weeks * treatment with any drug that could interfere with the glucose level * any serious medical condition * females who are pregnant, have intention of becoming pregnant or are breastfeeding
mscs combined with cd25 monoclonal antibody and calcineurin inhibitors for treatment of steroid-resistant agvhd

Conditions: Acute Graft-versus-host Disease

Summary: the purpose of this study is to compare the efficacy of cd25 monoclonal antibody and calcineurin inhibitors with or without mesenchymal stem cells (mscs) in treating patients with steroid-resistant acute graft-versus-host disease (agvhd) after allogeneic hematopoietic stem cell transplantation.

allogeneic hematopoietic stem cell transplantation (allo-hsct) is an effective therapy for several hematological disorders. although good progress has been made in the prevention and treatment of side effects associated with transplantation, agvhdremains a common and life-threatening complication with poor prognosis. corticosteroids are still acted as the first-line treatments of agvhd, with a response rate of 50-80. however, those who failed to initial therapy only have 10-30% long-term survival. mesenchymal stromal cells (mscs) are a form of multipotent adult stem cells that can be isolated from many tissues, such as bone marrow (bm), adipose tissue and umbilical cord. such cells possess the capacity to suppress immunological responses, support hematopoiesis and repair tissues. clinical applications of human mscs are evolving rapidly for preventing and treating gvhd. although the results are still controversy, most prospective and retrospective data suggest that mscs are effective to agvhd. in the present study, the investigators will prospectively evaluate the efficacy and safety of ex-vivo-expanded bm-derived mscs from third-party donors combined with cd25 monoclonal antibody and calcineurin inhibitors in treating patients with agvhd.

Eligibility criteria:
inclusion criteria: * age of 14-65 years * steroid-resistant agvhd * subjects (or their legally acceptable representatives) must have signed an informed consent document exclusion criteria: * any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * patients with any conditions not suitable for the trial (investigators' decision)

Keywords: hematopoietic stem cell transplantation mesenchymal stem cells cd25 monoclonal antibody acute graft-versus-host disease
effects of vr in children with dcd: randomized controlled trial

Conditions: Virtual Reality; Developmental Coordination Disorder; Visual Perceptual Weakness; Motor Skills Disorders; Sensory Disorder; Executive Dysfunction; Participation, Patient

Summary: the aim of the study is to examine the effect of vr application on motor, cognitive and sensory-perceptual skills, and activity and participation levels in children with dcd. the hypotheses on which the study proposal is based are as follows: 1. h0: vr application has no effect on motor skills in children with dcd. h1: vr application has an effect on motor skills in children with dcd. 2. h0: vr application has no effect on cognitive skills in children with dcd. h1: vr application has an effect on cognitive skills in children with dcd. 3. h0: vr application has no effect on sensory-perception skills in children with dcd. h1: vr application has an effect on sensory-perception skills in children with dcd. 4. h0: vr application has no effect on the functional independence levels in daily living activities in children with dcd. h1: vr application has an effect on the functional independence levels in daily living activities in children with dcd. 5. h0: vr application has no effect on participation levels in children with dcd. h1: vr application has an effect on participation levels in children with dcd.

within the scope of our aims; * to determine the gross motor skill levels of children with dcd and to obtain the effect of vr application on gross motor skill levels. * to determine the executive function skill levels of children with dcd and to obtain the effect of vr application on executive function skill levels. * to determine the sensory-perception skill levels of children with dcd and to obtain the effect of vr application on sensory-perception skill levels. * to determine the functional independence of children with dcd in daily life and to obtain the effect of vr application on their functional independence levels. * it is aimed to determine the participation levels of children with dcd and to obtain the effect of vr application on their participation levels.

Eligibility criteria:
inclusion criteria: * being between 5-8 years old, * it is to get 15-46 points from the developmental coordination disorder questionnaire for ages 5-7 and 15-55 points for ages 8. exclusion criteria: * those who are receiving any other therapy program, * have vision (other than glasses) or hearing problems, * children with any neurological disorder will not be included in the study.

Keywords: virtual reality visual perceptual motor skills developmental coordination disorder sensory perception cognition participation
inhaled salbutamol in elective caesarean section

Conditions: Postnatal Pulmonary Adaptation; Cesarean Section

Summary: the lungs of the fetus are filled with fluid and it is essential that fetal lung fluid is cleared at birth. this process is mediated through the activation of airway epithelial sodium channels (enac). in animals, enac is considered crucial for postnatal pulmonary adaptation. in humans, postnatal enac expression is dependent on gestational age and its activity, measured as nasal potential difference, correlates with lung compliance. therefore, in the human newborn infant enac may be important for physiologic postnatal adaptation. the activity of enac is increased by beta-agonists, such as salbutamol. we hypothesize that low pulmonary expression or activity of enac in the perinatal period causes delayed clearance of lung fluid and thereby contributes to the risk for development of transient tachypnea of the newborn (ttn) in term infants born by caesarean section (cs).

we hypothesize that low pulmonary expression or activity of enac in the perinatal period causes delayed clearance of lung fluid and thereby contributes to the risk for development of transient tachypnea of the newborn (ttn) in term infants born by caesarean section (cs). the aim of this study is to evaluate whether the respiratory status, measured by a transthoracic ultrasound method and lung compliance, of newborns infants born by cs can be improved by inhaled salbutamol at 30-60 minutes of age. 62 infants will be included and randomized to receive salbutamol or placebo-inhalations in a double-blind manner.

Eligibility criteria:
inclusion criteria: * healthy singleton pregnancy * cesarean section at 37 + 0 to 41 + 6 gestational weeks exclusion criteria: * clinically significant congenital malformations * birth weight \< 2000 grams * intubation * 200 bp for more than 5 min * relevant medication of the mother, e.g. albetol, beta-agonists (e.g. salbutamol, salmeterol), corticosteroids * the suspicion of/confirmed pneumothorax or infection

Keywords: lung fluid postnatal adaptation salbutamol albuterol epithelial sodium channel
phase ii study of taxotere in combination with exisulind in non-small cell lung cancer (nsclc) patients

Conditions: NSCLC

Summary: the purpose of this study is to determine if the combination of taxotere and exisulind is an effective and safe treatment for patients with advanced nsclc who have failed a prior platinum-containing regimen.


Eligibility criteria:
inclusion criteria: histologically documented advanced cancer or advanced platinum-refractory non-small cell lung cancer. platinum refractory defined as progressive disease during a platinum regimen or within 6 months following treatment. negative serum pregnancy test, if fertile female. have not taken sulindac (clinoril®) on regular basis for any indication for one week prior to enrollment and willing to remain off of sulindac for the duration of the study. \> 18 years or of legal age. male patients, or non-pregnant and non-lactating female patients either using adequate birth control (oral contraceptives or provera), surgically sterile or post-menopausal. willingness to remain off chronic nsaids (with the exception of ibuprofen, naproxen, or aspirin) for duration of the study. low dose aspirin for cardiovascular prevention is acceptable. no treatment with any other chemotherapy or radiotherapy within 2 weeks prior to entering the study. exclusion criteria: any condition or any medication which may interfere with the conduct of the study. known hypersensitivity to sulindac (clinoril®) or taxanes. use of an investigational medication or device within one month of initiating study therapy.
scs for the treatment of chronic pain of the upper extremities

Conditions: Upper Extremity Pain

Summary: this is a prospective, multi-center post-market study of the senza system in subjects with chronic, intractable pain of the upper extremities. data at follow-up visits will be compared to baseline data collected at the beginning of the study.


Eligibility criteria:
key inclusion criteria: 1. have been diagnosed with chronic, intractable pain of an upper extremity of neuropathic origin, which has been refractory to conservative therapy for a minimum of 3 months. 2. have an average pain intensity (over a period of 7 days) of an upper extremity of ≥ 5 out of 10 cm on the visual analog scale (vas) at enrollment. 3. be on stable pain medications for at least 28 days and be willing to stay on those medications with no dose adjustments until activation of the permanently implanted scs device. 4. be 18 years of age or older at the time of enrollment. 5. be an appropriate candidate for the surgical procedures required in this study. 6. be capable of subjective evaluation, able to read and understand english-written questionnaires, and are able to read, understand and sign the written inform consent in english. 7. have stable neurological status measured by motor, sensory and reflex function. key exclusion criteria: 1. have a medical condition or pain in other area(s), not intended to be treated with scs, that could interfere with study procedures. 2. have a current diagnosis of a progressive neurological disease. 3. have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure. 4. have mechanical spine instability as determined. 5. have significant stenosis, based on mri. 6. have an existing drug pump and/or another active implantable device (switched on or off) such as a pacemaker or other scs devices. 7. have a condition currently requiring or likely to require the use of whole body mri or diathermy. 8. be pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 2 years post-menopausal). 9. have within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs. 10. be involved in an injury claim under current litigation. 11. have a pending or approved worker's compensation claim. 12. have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcome, as determined by a psychologist.
biomarkers for initiating onsite and faster ambulance stroke therapies

Conditions: Stroke; Ischemic Stroke; Hemorrhagic Stroke

Summary: stroke is the first cause of death among spanish women and main cause of disability. reperfusion therapies of the occluded artery remain the only useful approach in acute ischemic stroke. however, the efficacy of these strategies is highly time-dependent and due to the need of neuroimaging (ct or mri) to differentiate between ischemic and hemorrhagic stroke, impossible to be performed at the pre-hospital level. the investigators aim to set-up a point of-care (poc) device to validate a biomarker panel differentiating ischemic and hemorrhagic stroke at the pre-hospital level using a blood sample and to validate a second biomarker panel for the early identification of patients with large vessel occlusions (lvo), which are candidates for mechanical thrombectomy. for that, the investigators will recruit a 300 patients' cohort with pre-hospital blood samples using available pocs for each of those markers.


Eligibility criteria:
inclusion criteria: * i.1: patients \> 18 years old. * i.2: stroke code activated by the coordinator centre. * i.3: \< 6 hours from symptoms onset. in the case of stroke with uncertain chronology or wake-up stroke, the initial time will be considered as the last moment the patient was seen fine. exclusion criteria: * e.1: prehospital diagnosis different of stroke. * e.2: impossibility of getting a prehospital blood sample. * e.3: refusal to provide the informed consent by the patient/relative.

Keywords: blood biomarkers stroke diagnosis stroke biomarkers reperfusion therapies acute stroke therapy prehospital stroke management
identifying toddlers and their parents who are suffering from posttraumatic distress following war and terror

Conditions: Stress Disorders, Post-Traumatic

Summary: the project is aimed at identifying children who are suffering from posttraumatic distress and increasing capacity to provide treatment for them and for their caretakers. the project will be implemented in 3 cities in israel, haifa, kiryat shmona and sderot, exposed to terrorism and the effects of war

a. screening of young children and implementation of treatment the screening will consist of self-report questionnaires and a clinical interview with parents, conducted by trained professional about exposure to traumatic events and resulting post-traumatic specific symptoms among the toddlers and their parents. the screening procedure is bases on the accumulated clinical experience and empirical data gained in the ongoing similar project in sderot. the level of cooperation by parents and teachers in the ongoing project has been exceptionally high, indicating a tremendous need for knowledge, skills and support. based upon our previous experience, it is anticipated well-baby clinic nurses will also be extremely interested participation. b. workshops for parents, teachers, nurses the knowledge and skills of preschool teachers and nurses working in all our projects sights (well baby clinics, day care centers and kindergartens) as well as parents will be increased by providing training regarding the impact of war related trauma on preschool children. workshops will better equip teachers, nurses and parents with knowledge about the emotional impact of trauma on young children and will increase the skills to help preschool children contain emotional distress as well as to help them in coping with the emotional consequences of trauma exposure. c. treatment interventions all toddlers identified with posttraumatic distress will receive dyadic treatment focused on dealing with posttrauma. dyadic treatment involving parents and children is aimed at increasing the attunement of parents to their toddlers and their needs in times of crises. local practitioners in sderot implementing this cutting-edge treatment received specialized training adjusted to the context of terror and trauma by a child trauma specialist from mount sinai medical center in new york. d. evaluation of treatment evaluation of treatment efficacy (dyadic treatment) will be assessed by pre and post interviews that will be conducted by trained professionals with all parents participating in the dyadic treatments in each of the three cities

Eligibility criteria:
inclusion criteria: * families with children between the age 1-6 years. * families living in sderot, kyriat shmona and haifa exclusion criteria: * severe developmental problems

Keywords: ptsd dyadic treatment war and terror posttraumatic symptoms among toddlers
emg analysis in abi: motor imagery and action

Conditions: Stroke; Quality of Life; Mirror Movement

Summary: this study focuses on electromyographic analysis of upper limb muscle activation in stroke survivors during motor imagery (mi) and action observation (ao) rehabilitation techniques. by measuring muscle activity in the wrist and finger flexors and extensors, the research seeks to understand the impact of mi and ao on motor function recovery post-stroke. conducted at the university of salamanca, the study involves stroke survivors participating in a series of three experimental sessions. the analysis will correlate electromyographic responses with functional independence, limb functionality, and cognitive factors. the research aims to contribute to the fields of occupational therapy and physiotherapy, offering insights into effective rehabilitation methods for improving quality of life in stroke survivors.

this study investigates muscle activation in the upper limbs of stroke survivors using electromyographic analysis during motor imagery (mi) and action observation (ao). stroke, a major cause of disability, often results in motor impairments in the upper limb, impacting daily activities. the research focuses on innovative rehabilitation techniques based on neuroplasticity, such as mi and ao, stimulated by the discovery of mirror neurons. the primary goal is to record upper limb muscle activation during mi and ao, using surface electromyography to measure activation in wrist and finger flexors and extensors. the study will also explore the relationship between electromyographic responses and factors like daily activity independence, limb functionality, quality of life, mental evocation ability, and cognitive impairment. conducted at the university of salamanca, the study will recruit stroke survivors for a three-session experimental protocol involving control, mi, and ao conditions. data will be analyzed with spss statistics, ensuring anonymity and ethical compliance. the research aims to enhance understanding of effective neurorehabilitation techniques, contributing to the fields of occupational therapy and physiotherapy.

Eligibility criteria:
inclusion criteria: * being over 18 years of age * diagnoses of established stroke * present limitations or motor response deficiencies in the upper limb * maintain cognitive functions with the ability to follow the instructions of the interventions and evaluations (moca\>14) exclusion criteria: * diagnosed with mental illness before the stroke * other systemic conditions on the central nervous system * cardiorespiratory system pathologies in severe cases * acute period, fever, muscle inflammation or myopathies * any type of vascular and organic insufficiency * liver disease or skin lesions in the area of application of the electrodes.

Keywords: stroke rehabilitation electromyography neuroplasticity upper linb neurorehabilitation
prostaglandin f2alpha in a human headache model

Conditions: Headache

Summary: the hypothesis of this study is that pgf2alpha does not induce headache or dilatation of brain vessels.


Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * primary headache * headache on the day of the investigation * hypertension * hypotension * pregnant/nursing * daily intake of medication (except oral contraceptives) * cardiovascular or central nervous system (cns) disease * drug/alcohol abuse * psychiatric disease
a registered cohort study on spastic paraplegia

Conditions: Spastic Paraplegia

Summary: the aim of this study is to determine the clinical spectrum and natural progression of hereditary spastic paraplegias(hsp) and related disorders in a prospective multicenter natural history study, to assess the clinical, genetic and epigenetic features of patients with spastic paraplegias to optimize clinicalmanagement..


Eligibility criteria:
inclusion criteria: * patients with the clinical diagnosis of spastic paraplegia * clinical diagnosis of patients with spastic paraplegia * unrelated healthy controls exclusion criteria: * decline to participate. * there are serious interferences with individual participation and adherence to the research protocol, including but not limited to neurological, psychological, and/or medical conditions.
neuropsychological functioning in children with attention-deficit/hyperactivity disorder.

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of this study is to evaluate the change in neuropsychological status from baseline to 6 months post-initiation of atomoxetine treatment in children ages 6 to 10.5 diagnosed with adhd.


Eligibility criteria:
a) patients: inclusion criteria: 1. patients must have adhd, be outpatients, who are at least 6 years of age and not more than 10 years 6 months of age at visit 1 so that all testing will be completed before the child reaches age 11. 2. patients must have moderately severe symptoms of adhd. 3. patients must be able to swallow study drug capsules. exclusion criteria: 1. patients must not have bipolar disorder, psychosis, autism, asperger's syndrome, pervasive developmental disorder, or seizure disorder. 2. patients must not be home-schooled. b) controls: subjects will be recruited by the investigator, age and gender-matched to the atomoxetine-treated patients. inclusion criteria: 1) control subjects must be assessed to be not diagnosed with a psychiatric disorder or a medically significant disorder exclusion criteria: 1) subjects must not be home-schooled.